AMR 2025 funding calls: Cycle 2

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today a funding solicitation with four distinct product themes:

• Therapeutics for infections caused by Gram-negative pathogens
• Diagnostics for typhoid fever for low-resource settings

Funding: varies according to project type and phase

Duration: No fixed limit

Research Authority due date: 4.12.25